Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Windtree Therapeutics (NASDAQ: WINT) Granted EU Patent for SERCA2a Activator Therapy for Heart Failure

April 17, 2023 at 12:14 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Windtree Therapeutics, Inc. (NASDAQ: WINT) is engaged as a biotechnology company, which is focused on late-stage treatments for cardiovascular disorders. Shares of the cardiovascular biotech company are skyrocketing 213%, through afternoon trading on Monday, April 17, 2023. Over the past three months, Windtree Therapeutics has seen an average daily volume of 147,720 shares. However, a volume of 4.15 million shares, or a dollar volume of around $62.08 million, has already exchanged hands through afternoon trading.

Shares of Windtree Therapeutics are surging after the company announced it has been granted Patent No. 3599243 by the European Patent Office. This patent, titled: “17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE,” grants protection until July 2038. The patent covers the revolutionary SERCA2a Activator class of drugs, which have dual mechanisms of action – they inhibit the Na+/K+ pump and activate SERCA2a, in addition to offering pure SERCA2a activators.

The SERCA2a enzyme, which is decreased in heart failure, has presented an opportunity for potential therapeutic advancement. Windtree’s strategy of dual-mechanism compounds, with istaroxime as its lead candidate for heart failure and cardiogenic shock treatment, is aiming to take advantage of this exciting chance.

Dual mechanism compounds are developed to provide both oral and intravenous therapies for heart failure treatment, whether it be an inpatient hospital stay for an acute case or an outpatient oral treatment for a chronic one.

Windtree Therapeutics is forging a multi-asset empire, centered around compounds with the capability to trigger SERCA2a. As part of its heart failure platform, they are also actively pursuing follow-up oral pre-clinical SERCA2a activator assets. Beyond istaroxime, Windtree boasts rostafuroxin, a novel, specifically designed medication targeting hypertensive patients with certain genetic profiles.

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Windtree Therapeutics (NASDAQ: WINT) Granted EU Patent for SERCA2a Activator Therapy for Heart Failure appeared first on Spotlight Growth.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article